## QUARTERLY ISSUER INFORMATION AND DISCLOSURE STATEMENT

March 31, 2012

## DNA DYNAMICS, INC.

1 Warwick Street, Royal Leamington Spa, Warwickshire, CV32 5LW, UK

Tel: +44 1926 460180 Facsimile: 407-585-1081

CUSIP No. 25600R101

## **ISSUER'S EQUITY SECURITIES**

COMMON STOCK \$.001 Par Value 350,000,000 Common Shares Authorized 275,584,884 Shares Issued and Outstanding

PREFERRED STOCK \$.001 Par Value 20,000,000 Shares Authorized 10,000,000 Shares Issued and Outstanding

## FORWARD LOOKING STATEMENTS

THIS INITIAL COMPANY INFORMATION AND DISCLOSURE STATE, IN PARTICULAR, "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" AND "BUSINESS," INCLUDE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THESE STATEMENTS REPRESENT THE COMPANY'S EXPECTATIONS OR BELIEFS CONCERNING, AMONG OTHER THINGS, FUTURE REVENUE, EARNINGS, AND OTHER FINANCIAL RESULTS, PROPOSED ACQUISITIONS AND NEW PRODUCTS, ENTRY INTO NEW MARKETS, FUTURE OPERATIONS AND OPERATING RESULTS, FUTURE BUSINESS AND MARKET OPPORTUNITIES. THE COMPANY WISHES TO CAUTION AND ADVISE READERS THAT THESE STATEMENTS INVOLVE RISK AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE EXPECTATIONS AND BELIEFS CONTAINED HEREIN. FOR A SUMMARY OF CERTAIN RISKS RELATED TO THE COMPANY'S BUSINESS, SEE "RISK FACTORS." UNDER "DESCRIPTION OF BUSINESS."

Unless the context requires otherwise, references to the Company or Issuer are to DNA Dynamics, Inc.

## PART A GENERAL COMPANY INFORMATION

Cautionary Factors That May Affect Future Results (Cautionary Statements Under the Private Securities Litigation Reform Act of 1995)

The disclosure and analysis set forth herein contains certain forward looking statements, particularly statements relating to future actions, performance or results of current and anticipated products and services, sales efforts, expenditures, and financial results. From time to time, the Company also provides forward-looking statements in other publicly-released materials, both written and oral. Forward-looking statements provide current expectations or forecasts of future events such as new products or services, product approvals, revenues, and financial performance. These statements are identified as any statement that does not relate strictly to historical or current facts. They use words such as "anticipates," "intends," "plans," "expects," "will," and other words and phrases of similar meaning. In all cases, a broad variety of assumptions can affect the realization of the expectations or forecasts in those statements. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially.

The Company undertakes no obligation to update any forward-looking statements, but investors are advised to consult any further disclosures by the Company on this subject in its subsequent filings. Furthermore, as permitted by the Private Securities Litigation Reform Act of 1995, the Company provides these cautionary statements identifying risk factors, listed below, that could cause the Company's actual results to differ materially from expected and historical results. It is not possible to foresee or identify all such factors. Consequently, this list should not be considered an exhaustive statement of all potential risks, uncertainties and inaccurate assumptions.

## **RISK FACTORS**

**No Active Market.** Although the Company's shares are listed on the Pink Sheets listing service, the Company believes that the public trading price may be an inaccurate representation of the value of the Company because there is little or no trading volume in the Company's shares and no analysts or NASD market makers actively follow the Company.

We have never issued a Dividend and don't anticipate any Dividends in the future. DNA Dynamics has never issued a dividend and we do not anticipate paying dividends on our common stock in the foreseeable future. Furthermore, we may also be restricted from paying dividends in the future pursuant to subsequent financing arrangements or pursuant to Delaware law.

You could be diluted from the Issuance of additional Common and Preferred Stock. DNA Dynamics is authorized to issue up to 350,000,000 shares of common stock and 20,000,000 shares of preferred stock. To the extent of such authorization, our board of directors will have the ability, without seeking shareholder approval, to issue additional shares of common stock in the future for such consideration as the board may consider sufficient. The issuance of additional common stock in the future may reduce your proportionate ownership and voting power.

Volatility of Stock Prices. In the event that there is an established public market for the Company's Common Stock, market prices will be influenced by many factors and will be more subject to significant fluctuations in response to variations in operating results of the Company and other factors such as investor perceptions of the Company, supply and demand, interest rates, general economic conditions and those specific to the industry, developments with regard to the Company's activities, future financial condition and management.

Applicability of Low Priced Stock Risk Disclosure Requirements. The Common Stock of the Company may be considered a low priced security under rules promulgated under the Securities Exchange Act of 1934. Under these rules, broker-dealers participating in transactions in low priced securities must first deliver a risk disclosure document which describes the risks associated with such stocks, the broker-dealer's duties, the customer's rights and remedies, certain market and other information, and make a suitability determination approving the customer for low priced stock transactions based on the customer's financial situation, investment experience and objectives. Broker-dealers must also disclose these restrictions in writing to the customer, obtain specific written consent of the customer, and provide monthly account statements to the customer. With all these restrictions, the likely effect of designation as a low priced stock will be to decrease the willingness of broker-dealers to make a market for the stock, to decrease the liquidity of the stock and to increase the transaction cost of sales and purchases of such stock compared to other securities.

#### PART A. GENERAL COMPANY INFORMATION

Item I. The exact name of the issuer and its predecessors (if any):

### DNA Dynamics Corporation, a Delaware corporation

## Item II. The address of its principal executive officers:

1 Warwick Street Leamington Warwickshire CV32 5LW Telephone- +44 1926 460180 Facsimile-

## Item III. The jurisdiction(s) and date of the issuer's incorporation:

Delaware July 1, 1981

## PART B. SHARE STRUCTURE

## Item IV. The exact title of securities outstanding:

Common Stock, \$.001 par value per share Cusip Number – 25600R101 Trading Symbol – DNAD

## Item V. Par or stated and description of the security:

- A. Our outstanding security is our Common Stock and Preferred Series A Stock each with a \$.001 par value.
- B. Each holder of Common Stock is entitled to one vote for each share held of record on each matter submitted to vote to stockholders, including election of directors. Stockholders do not have any right to cumulate votes on the election of directors. Each holder of Common Stock is entitled to share ratably in distributions to stockholders and to receive ratably such dividends as may be declared by the Board of Directors out of funds legally available. Therefore, in the event of our liquidation, dissolution or winding up, the holders of Common Stock will be entitled to receive, after payment of all of our debts and liabilities, and of all sums to which holders of any outstanding preferred stock, if any, may be entitled, the distribution of any of our remaining assets. Holders of our Common Stock have no conversion, exchange, sinking fund, redemption or appraisal rights (other than such as may be determined by the Board of Directors in its sole discretion) and have no preemptive rights to subscribe for any of our securities. There are no provisions in our Articles of Incorporation or By-Laws that would delay, defer or prevent a change of control of the Company.
- C. Each holder of Preferred Stock is entitled to one hundred votes for each share held of record on each matter submitted to vote to stockholders, including election of directors. Preferred Stock is convertible into Common Stock on a 1-for-1 basis and votes at 100:1. Stockholders do not have any right to cumulate votes on the election of directors. Each holder of Preferred Stock is entitled to share ratably in distributions to stockholders and to receive ratably such dividends as may be declared by the Board of Directors out of funds legally available. Therefore, in the event of our liquidation, dissolution or winding up, the holders of Preferred Stock will be entitled to receive, after payment of all of our debts and

liabilities, and of all sums to which holders of any outstanding common stock, if any, may be entitled, the distribution of any of our remaining assets.

Item VI. The number of shares or total amount of the securities outstanding for each class of securities authorized:

March 31, 2011	Authorized	Outstanding	Freely	Total	Total
	Shares	Shares	Trading	Number of	Number of
			Shares	Beneficial	Shareholders
				Shareholders	of Record
Common	350,000,000	275,584,884	178,656,293	2	50
Preferred	20,000,000	10,000,000	0	2	2

#### PART C BUSINESS INFORMATION

## Item VII. The name and address of the transfer agent:

Our transfer agent is:

Stalt, Inc. 671 Oak Grove Avenue, Suite C Menlo Park, CA 94025 Tel: 650 321-7111

Fax: 650 321-7113

The transfer agent is registered under the Exchange Act and its regulatory authority is the Securities & Exchange Commission.

## Item VIII. The nature of the issuer's business:

## A. Business Development.

DNA Dynamics, Inc. is a corporation formed under the laws of the State of Delaware. DNA Dynamics, Inc. was originally incorporated on July 1, 1981.

On  $20^{th}$  January, 2011, 50,000,000 shares of Common Stock was issued to David Lovatt as remuneration for his role as Corporate Secretary.

On 16<sup>th</sup> June 2011, 15,000,000 shares of Common Stock were issued to Edward Blincoe for his role as President, Chairman and Chief Executive Officer.

On ,  $16^{\rm th}$  June 2011, David Lovatt returned 35,000,000 shares of Common Stock of DNA Dynamics.

On 27<sup>th</sup> September, 5,000,000 shares of Preferred Series A Stock of DNA Dynamics were issued to David Lovatt as remuneration for his role as Chief Operating Officer.

During the past three years the Company has not been in bankruptcy, receivership or involved in any similar proceeding.

The Company is not in default in the terms of any note, loan, lease, or other indebtedness or financing arrangements requiring the Company to make payments, but has an overdue note for which arrangements to settle are in negotiation. Except as described herein, the Company has not during the past three years had any other stock splits, stock dividends, mergers, reorganization or similar transactions. The Company has not been the subject of any delisting by a securities exchange or a deletion from the OTC Bulletin Board. There are no current, pending or threatened legal proceedings or administrative actions against the Company nor has there been for the past three years.

#### **B.** Business of issuer:

The Company's Standard Industrial Code (SIC) is 5734-01. The company provides Mobile Games & Apps for Smartphones.

The Company operates its business at its offices located at 1, Warwick Street, Leamington, Warwickshire, CV32 5LW

The Company has an address in New York at 244, Fifth Avenue, Suite 1751, New York, New York, 10001.

## Item IX. The nature of products or services offered:

DNA Interactive and DNA Studios operate under a UK subsidiary, Helical Games Limited (HGL).

HGL was formed in 2011 primarily as an ownership vehicle for the two operating subsidiaries and holds all of the issued share capital of the two subsidiaries. DNAD owns all of the issued share capital of HGL.

DNA Interactive Limited (DNAI) was formed in the United Kingdom in 2010, with authorized common stock of 1000 shares. The organization is a Mobile Platform Application and Games Development company. DNAI is a wholly owned subsidiary of HGI.

The Company was acquired by DNA Dynamics, Inc. (PK:DNAD) in November 2010. (The company was formerly Appache Mobile).

DNA Studios Limited was formed in the United Kingdom in 2007, with authorized common stock of 100 shares. The organization is a Video Games Development company. The company was acquired by DNA Dynamics in April 2011. (The company was formerly Slam Productions)

The companies operate as wholly owned subsidiaries of DNA Dynamics, Inc. where the Authorized Share Capital is 350,000,000 Common Shares and the Issued Share Capital is currently around 345,584,884. The common shares are currently trading at around \$0.004 per share.

The Company has 9 full time employee and 5 part time employees.

The Company has not incurred and do not anticipate incurring costs in complying with federal, state and local environmental laws.

#### Item X. The nature and extent of the issuer's facilities:

The Company's principal corporate office is located at 1 Warwick Street, Learnington, Warwickshire, CV32 5LW, UK where it uses approximately 2600 square feet. The Company believes that this space is adequate for its current operations, but is seeking to secure office space with more modern facilities.

#### PART D. MANAGEMENT STRUCTURE AND FINANCIAL INFORMATION

## Item XI. The name of the Chief Executive Officer and members of the Board of Directors, as well as control persons:

The following tables set forth certain information regarding beneficial ownership of DNA Dynamics's common stock and preferred stock as of March 31, 2012, by (i) each person (or group of affiliated persons) who is known by us to beneficially own more that 5% of the outstanding shares of our common stock, (ii) each director and executive officer of DNA Dynamics, Inc., and (iii) all executive officers and directors of DNA Dynamics, Inc., as a group. There are no conflicts of interest. Unless indicated otherwise, the address for each officer, director and 5% stockholder is c/o DNA Dynamic, Inc., at 1 Warwick Street, Leamington, Warwickshire, CV32 5LW, UK

Directors, Executive and Management		Number	% Of Class
Edward Blincoe	(2)	15,000,000 Common Stock 5,000,000 Preference A Stock	5% 50%
David Lovatt	(3)	15,000,000 Common Stock 5,000,000 Preference A Stock	5% 50%
Paul Ranson		8,000,000 Common Stock	2%
Craig Weeks		8,000,000 Common Stock	2%

## See Notes Below

- (1) Except as otherwise indicated below, the persons and entity named in the table have sole voting and investment power with respect to all shares of preferred stock shown as beneficially owned by them, subject to applicable community property laws. Each share of preferred stock converts into one (1) share of common stock, and each share of preferred stock carries 100 votes.
- (2) Executive Chairman of the Board of Directors, President and Shareholder, Mr. Blincoe owns 5,000,000 shares of Preferred Stock and 15,000,000 Common Stock.
- (3) Director, Chief Operating Officer, Secretary and Shareholder, Mr. Lovatt owns 5,000,000 shares of Preferred Stock and 15,000,000 Common Stock.

**Ed Blincoe**, 36, *President*, *CEO* & *Chairman of the Board of Directors* – Mr. Blincoe has worked in the videogames industry for 13 years for companies such as Codemaster

s, SouthPeak Interactive, 505 Games and GamesDomain. From November 2008 to mid-2010 Mr. Blincoe was European Marketing Director for videogames publisher SouthPeak Interactive and lead the European marketing team on console and PC games such as the licensed Horrid Henry (based on the ITV children's cartoon), Section 8 (for PC and XBox 360) 3D Dot Game Heroes and Velvet Assassin. From November 2005 to June, 2008 Mr. Blincoe was the Senior Marketer for the launch of The Lord of the Rings Online in Europe which is still today considered one of the biggest MMO (Massively Multiplayer Online) gaming releases of all time. Ed was also responsible for the launches and subsequent post launch

marketing for Dungeons and Dragons Online, Archlord, RF Online, Time of Defiance, Darkaron, Dream of Mirror Online and Infinity Online. Mr. Blincoe is not a director or officer of a public company filing reports in accordance with the Securities Act of 1934.

**David Lovatt**, 37, *Corporate Secretary* - An experienced and technically aware professional with a successful career in Commercial & Sales Management who is hands on, creative, passionate, motivated, goal orientated and has an eye on the detail and not just the broad approach. David has a long history is sales execution, technology start-ups and development of VC backed and Public Companies. David was the Managing Director of Enable Software from July 2008 to April 2011 and the CEO of Cloud Centric Systems, Inc from October 2009 to February 2011. From July 2010 to April 2011, David was the President of Mobile Media Unlimited Holdings, Inc. From June 2007 to August 2008, Mr. Lovatt was the Global Partnerships Manager for MXSweep Limited. From March 2004 to June 2007, Mr. Lovatt was the Group Commercial Manager for Eclipse Group Solutions Limited.

## **Management Legal/Disciplinary History**

During the past 5 years none of the officers or directors of DNA Dynamics, Inc. have been subject to Legal/Disciplinary action by any regulatory or government body, including any civil, criminal or injunctive action or judgment. Furthermore, none of the officers and directors has filed bankruptcy during the past 5 years.

## **Related Party Transactions and Family Relationships**

There are no related party transactions within The Company, nor do the officers and directors have any family relationships between other shareholders, creditors or other parties involved with the business.

## **Summary Compensation Table**

				Restricted	All Other
Name and			Other Annual	Stock Awards	Compensation
Principal Position	<u>Year</u>	<u>Salary</u>	Compensation		
Ed Blincoe	2011	\$35,000	0	15,000,000	0
President &	2010	\$0.00	0	0	5,000,000 pref A Stock
CEO	2009	\$0.00	0	0	0
David Lovatt	2011	\$35,000	0	15,000,000	5,000,000 pref A Stock
Director	2010	\$0.00	0	0	0
	2009	\$0.00	0	0	0

Members of the Board serve until the next annual meeting of shareholders and until their successors are elected and qualified. Officers are appointed by and serve at the discretion of the Board.

## Item XII. Financial information for the issuer's most recent fiscal period:

The unaudited financial statements of the issuer are hereby incorporated by reference and are to be posted soon on www.otcmarkets.com

## Item XIII. Similar financial information for such part of the two preceding years as the issuer or its predecessor has been in existence:

The unaudited financial statements of the issuer are hereby incorporated by reference and are to be posted soon on www.otcmarkets.com

#### Item XIV. Beneficial Owners.

Beneficial Owner	Number of Shares	% of total issued
Edward Blincoe, CEO C/O: DNA DYNAMICS, Inc. 1 Warwick Street Leamington CV32 5LW UK	15,000,000	5%
David Lovatt, COO C/O: DNA DYNAMICS, Inc. 1 Warwick Street Leamington CV32 5LW UK	15,000,000	5%

# Item XV. The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:

- 1. Investment Banker: Buckman, Buckman & Reid, Headquartesrs and Supervisory Office, 174 Patterson Avenue, Shrewsbury, NJ 07702
- **2.** Investor Relations Counsel: Elite Financial Communications, *581 Technology Park Suite 1009*, *Lake Mary*, *FL 32746-7127*, *407-585-1080*
- 3. Counsel for SEC Registration: Brenda Hamilton, Hamilton & Associates Law Group P.A., 101 Plaza Real South, Suite 201 South, Boca Raton, Florida 33432
- 4. Counsel for OTC Filings: John Thomas
- 5. Accountant: (USA) Jonathan Tillotson, CPA, Executive Outcome, 4571 Via Del Valle, Yorba Linda, CA 92886
- 6. Accountant: (UK) Paul Clewlow MICB, CBDip, PMDip, Paul Clewlow & Co., 21 Bracken Drive, Wolvey, Warwickshire LE10 3LS
- 7. Auditor: Malone Bailey LLP, Westchase District, 10350 Richmond Ave., Suite 800, Houston, TX 77042
- 8. Public Relations Consultant: None
- 9. Promoters: None

## Item XVI. Management's Discussion and Analysis or Plan of Operation:

## **Results of Operations**

**Results of Operations** 

Following is management's discussion of the relevant items affecting results for the year ending March 31st, 2012.

Revenues. The Company generated net revenues of \$57,065.34 during the three months ending March 31st, 2012 Management anticipates that future revenues will likely grow significantly. Due to the Company's business model and contracts agreed, both signed and verbal.

Cost of Sales. Cost of sales for the three months ending March 31st, 2012 is \$86,969. Management believes this excess of cost over sales is reasonable, given the recent history of the Company. Sales will progressively exceed their cost as the sales volume grows.

Salaries and Commission Expenses. The total amount of salaries paid to the three months to March 31st, 2012 was \$65,702.

Professional Fees, Licensing and Permits. Professional fees, licensing, and permits will grow modestly as the Company pursues admittance to the OTCQB tier of OTC Markets.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months to March 31st, 2012 \$66,847. Given the history of the Company's operations, this is reasonable.

Liquidity and Capital Resources

The Company has financed its operations with cash generated from ongoing business activities as well as from unsecured loans.

## PART E. ISSUANCE HISTORY

## Item XVII List of Securities Offerings and Shares Issued for Services in the quarter

		Shares	Shares	Price		Total	Nature of	Jurisdiction	Trading	
Description	Date	Offered	Sold	Offered	Price Paid	Amount	the offering	of offering	Status	Legend
Hanover Holdings	02/22/2012	21,500,000	21,500,000	\$0.001372	\$0.001372	\$29,500	504	Texas	Free	None
Fairhills Capital	03/21/2012	22,000,000	22,000,000	\$0.001000	\$0.001000	\$22,000	504	Delaware	Free	None

### PART F EXHIBITS

**Item XVIII** Material Contracts

None

Item XIX Articles of Incorporation and Bylaws

- Articles of Incorporation (See Articles of Incorporation in Filing section of PinkSheets.com)
   Bylaws (See Corporation Bylaw in Filing section of PinkSheets.com)

#### Purchases of Equity Securities by the Issuer and Affiliated Purchasers Item XX

None

#### Item XXI Issuer's Certifications

I, Ed Blincoe, certify that:

- 1. I have reviewed this Disclosure Statement of DNA Dynamics, Inc.;
- 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
- 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: March 30<sup>th</sup> 2012

Ed Blincoe President & CEO

Report and Accounts
For the 3 Month period ending
31 March 2012

DNA DYNAMICS INC.	
Registered number:	OTC Pink
Directors' Report	

The directors present their report and accounts for the period ended 31 March 2012.

## **Principal activities**

The company's principal activity during the year continued to be the development of applications for mobile devices.

## **Directors**

The following persons served as directors during the period:

E Blincoe D Lovatt

## **Small company provisions**

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

This report was approved by the board on 30 April 2012 and signed on its behalf.

E Blincoe Director

# DNA DYNAMICS INC. Accountants' Report

## Accountants' report to the directors of DNA DYNAMICS INC.

We have compiled the attached Financial Statements from the records and information provided to us by the management of the company.

The Balance Sheet, statement of operations, changes in stockholders equity and cash flows for the quarter ended 31st March 2012 have been prepared in accordance with the financial reporting standards applicable to small companies.

We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.

P. Clewlow & Co Accountants & Certified Bookkeepers

21 Bracken Drive Wolvey Warwickshire LE10 3LS

30 April 2012

# DNA DYNAMICS INC. Profit and Loss Account for the period from 1 January 2012 to 31 March 2012

	Notes	2012 \$
Turnover	2	70,207
Cost of sales		(86,969)
Gross loss		(16,762)
Administrative expenses		(132,549)
Operating loss		(149,311)
Loss on ordinary activities before taxation		(149,311)
Tax on loss on ordinary activities		-
Loss for the period		(149,311)

## DNA DYNAMICS INC. Balance Sheet as at 31 March 2012

ı	Notes		2012 \$
Fixed assets Intangible assets Tangible assets Investments	3 4 5		86,592 3,367 (49,000) 40,959
Current assets Debtors	6	56,799	
Creditors: amounts falling due within one year	7	(535,189)	
Net current liabilities			(478,390)
Total assets less current liabilities			(437,431)
Creditors: amounts falling due after more than one year	8		(73,464)
Net liabilities			(510,895)
Capital and reserves Called up share capital Revaluation reserve Profit and loss account	9 10 11		280,585 1,258,391 (2,049,871)
Shareholders' funds	12		(510,895)

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

Members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

E Blincoe Director Approved by the board on 30 April 2012

## **Cash Flow Statement**

## for the period from 1 January 2012 to 31 March 2012

	2012 \$
Cash generated from operations	Φ
Operating loss	(149,311)
Reconciliation to cash generated from operations:	
Increase in debtors	(56,799)
Increase in creditors	228,597
	22,487
Application of cash	
Tax paid	1,579
Purchase of intangible fixed assets	(18,296)
-	(16,717)
Net increase in cash	5,770
Cash at bank and in hand less overdrafts at 1 January	-
Cash at bank and in hand less overdrafts at 31 March	5,770
Consisting of:	
Overdrafts	(5,770)

#### **Notes to the Accounts**

for the period from 1 January 2012 to 31 March 2012

#### 1 Accounting policies

#### Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

#### Turnover

Turnover represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

#### Stocks

Stock is valued at the lower of cost and net realisable value.

#### Deferred taxation

Full provision is made for deferred taxation resulting from timing differences between the recognition of gains and losses in the accounts and their recognition for tax purposes. Deferred taxation is calculated on an un-discounted basis at the tax rates which are expected to apply in the periods when the timing differences will reverse.

#### Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

2	Turnover	2012	
	Turnover attributable to geographical markets outside the UK	58.0%	
3	Intangible fixed assets Goodwill:		\$
	Cost At 1 January 2012 Additions		68,296 18,296
	At 31 March 2012		86,592
	Amortisation		
	At 31 March 2012		-
	Net book value At 31 March 2012		86,592
	At 31 December 2011		68,296

## DNA DYNAMICS INC. Notes to the Accounts

for the period from 1 January 2012 to 31 March 2012

4	Tangible fixed assets		
			Plant and
			machinery
			etc \$
	Cost		Þ
	At 1 January 2012		3,367
	At 31 March 2012		3,367
	74 01 Maron 2012		0,007
	Depreciation		
	At 31 March 2012		-
	Net book value		
	At 31 March 2012		3,367
	At 31 December 2011		3,367
5	Investments		
			Investments in
			subsidiary undertakings
			\$
	Cost		•
	At 1 January 2012		(49,000)
	At 31 March 2012		(49,000)
6	Debtors	2012	
0	Debiois	2012 \$	
		Ť	
	Trade debtors	56,520	
	Other debtors	279	
		56,799	
_		2012	
7	Creditors: amounts falling due within one year	2012 \$	
		Ą	
	Bank loans and overdrafts	319,720	
	Trade creditors	91,475	
	Amounts owed to group undertakings and undertakings in which the		
	company has a participating interest	30,063	
	Corporation tax	1,579	
	Other taxes and social security costs Other creditors	89,702 2,650	
	Other ordanals		
		535,189	

## **Notes to the Accounts**

for the period from 1 January 2012 to 31 March 2012

8	Creditors: amounts falling due aft	2012 \$		
	Trade creditors Other creditors			61,340 12,124
				73,464
9	Share capital	Nominal value	2012 Number	2012 \$
	Allotted, called up and fully paid: Ordinary shares	£1 each	-	280,585
		Nominal value	Number	Amount \$
	Shares issued during the period: Ordinary shares	£1 each	-	79,521
10	Revaluation reserve			2012 \$
	At 1 January 2012			1,258,391
	At 31 March 2012			1,258,391
11	Profit and loss account			2012 \$
	At 1 January 2012 Loss for the period			(1,900,560) (149,311)
	At 31 March 2012			(2,049,871)
12	Stockholders Equity Class of Equity ( Par value)	Authorised	Issued	Value \$
	Preferred Stock Series A \$.001 issued & outstanding	20,000,000	5,000,000	5,000
	Issued in Period		5,000,000	5,000
	Common Stock \$.001 issued & outstanding	350,000,000	275,584,884	275,585
				280,585

# DNA DYNAMICS INC. Notes to the Accounts for the period from 1 January 2012 to 31 March 2012

# Statement of Changes in Shareholders Equity for the period ended March 31st 2012

PREFERRED STOCK - SERIES A	Issued	Value \$
Balance as at 31st December 2011	5,000,000	5,000
Balance as at 31st March 2012	5,000,000	5,000
COMMON STOCK		
Balance as at 31st December 2011 Shares issued in period	196,063,145 79,521,739	196,063 79,522
Balance as at 31st March 2012	275,584,884	275,585
TOTAL EQUITY	280,584,884	280,585
RETAINED EARNINGS		\$
Balance as at 31st December 2011 Net loss for the current period		(1,900,560) (149,311)
Balance as at 31st March 2012		(2,049,871)

## **Profit and Loss Account**

## for the period from 1 January 2012 to 31 March 2012

for the information of the directors only

	2012 \$
Sales	70,207
Cost of sales	(86,969)
Gross loss	(16,762)
Administrative expenses	(132,549)
Operating loss	(149,311)
Loss before tax	(149,311)